Orgenesis: Funding, Investors & Team (Oct 2026)
Orgenesis is a company in the development stage that has come up with a unique therapeutic approach for treating diabetes. Their method involves using new functional tissues created from the patient's own existing organs to correct malfunctioning organs. Specifically, Orgenesis focuses on converting liver cells into insulin-producing cells, a process known as Autologous Insulin Producing (AIP) cell transplantation. This technique holds promise as a replacement for beta cells, which is currently the most effective treatment for Insulin Dependent Diabetes Mellitus (IDDM) but has limitations due to a shortage of donor tissue and the risk of rejection by the patient's immune system. By utilizing the patient's own tissue, Orgenesis believes they can overcome these challenges and eliminate the risk of transplant rejection. The company has conducted successful studies using human liver tissues, leading to the development of a comprehensive plan for initiating clinical testing. Following FDA guidelines, Orgenesis plans to begin phase I clinical trials in the near future and launch phase II trials within a year.
Orgenesis has raised $2.6M across 2 funding rounds on record, the most recent an undisclosed round of $1.6M announced in Mar 2024.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Orgenesis Company Profile and Key Stats
Latest funding round on record: Mar 2024.
Orgenesis Funding Rounds
Orgenesis raised $1.0M in an undisclosed round announced in Sep 2023.
6 months later, an undisclosed round of $1.6M was announced in Mar 2024.
Orgenesis Founders and Leadership Team
Contact details for the Orgenesis team: 1 of 1 has an email address on file.
Start 14-day free trial →Orgenesis Funding Compared to Other Biotechnology Startups
Orgenesis' latest round of $1.6M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Orgenesis in Biotechnology and White Plains
Companies Similar to Orgenesis
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Orgenesis Funding FAQs
What does Orgenesis do?
Orgenesis is a company in the development stage that has come up with a unique therapeutic approach for treating diabetes. Their method involves using new functional tissues created from the patient's own existing organs to correct malfunctioning organs. Specifically, Orgenesis focuses on converting liver cells into insulin-producing cells, a process known as Autologous Insulin Producing (AIP) cell transplantation. This technique holds promise as a replacement for beta cells, which is currently the most effective treatment for Insulin Dependent Diabetes Mellitus (IDDM) but has limitations due to a shortage of donor tissue and the risk of rejection by the patient's immune system. By utilizing the patient's own tissue, Orgenesis believes they can overcome these challenges and eliminate the risk of transplant rejection. The company has conducted successful studies using human liver tissues, leading to the development of a comprehensive plan for initiating clinical testing. Following FDA guidelines, Orgenesis plans to begin phase I clinical trials in the near future and launch phase II trials within a year.
How much funding has Orgenesis raised?
Orgenesis has raised $2.6M across 2 rounds on record. The most recent is an undisclosed round of $1.6M announced in Mar 2024.
When did Orgenesis last raise funding?
Orgenesis' most recent funding round on record is an undisclosed round of $1.6M, announced in Mar 2024.
Who founded Orgenesis?
FundedIQ lists Sarah Ferber (Founder) at Orgenesis.
Where is Orgenesis headquartered?
Orgenesis is based in White Plains, New York, United States.
How many employees does Orgenesis have?
Orgenesis is in the 101-250 employee band.
How does Orgenesis' funding compare to other Biotechnology startups?
Orgenesis' latest round of $1.6M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Orgenesis Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Orgenesis is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.